These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27104900)

  • 1. Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study.
    Müller M; Kuiperij HB; Versleijen AA; Chiasserini D; Farotti L; Baschieri F; Parnetti L; Struyfs H; De Roeck N; Luyckx J; Engelborghs S; Claassen JA; Verbeek MM
    J Alzheimers Dis; 2016 Apr; 52(4):1321-33. PubMed ID: 27104900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selenium species in cerebrospinal fluid predicts conversion to Alzheimer's dementia in persons with mild cognitive impairment.
    Vinceti M; Chiari A; Eichmüller M; Rothman KJ; Filippini T; Malagoli C; Weuve J; Tondelli M; Zamboni G; Nichelli PF; Michalke B
    Alzheimers Res Ther; 2017 Dec; 9(1):100. PubMed ID: 29258624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid.
    Müller M; Jäkel L; Bruinsma IB; Claassen JA; Kuiperij HB; Verbeek MM
    Mol Neurobiol; 2016 Jul; 53(5):2894-2899. PubMed ID: 25895659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating miRNAs as potential biomarkers in Alzheimer's disease.
    Galimberti D; Villa C; Fenoglio C; Serpente M; Ghezzi L; Cioffi SM; Arighi A; Fumagalli G; Scarpini E
    J Alzheimers Dis; 2014; 42(4):1261-7. PubMed ID: 25024331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders--A Pilot Study.
    Müller M; Claassen JA; Kuiperij HB; Verbeek MM
    J Alzheimers Dis; 2015; 46(3):605-9. PubMed ID: 25812850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease.
    Kiko T; Nakagawa K; Tsuduki T; Furukawa K; Arai H; Miyazawa T
    J Alzheimers Dis; 2014; 39(2):253-9. PubMed ID: 24157723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid in the dementias.
    Zetterberg H; Rohrer JD; Schott JM
    Handb Clin Neurol; 2017; 146():85-97. PubMed ID: 29110781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
    J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
    J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls.
    Denk J; Oberhauser F; Kornhuber J; Wiltfang J; Fassbender K; Schroeter ML; Volk AE; Diehl-Schmid J; Prudlo J; Danek A; Landwehrmeyer B; Lauer M; Otto M; Jahn H;
    PLoS One; 2018; 13(5):e0197329. PubMed ID: 29746584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frequent involvement of the amyloid pathway in prodromal dementia with Lewy bodies].
    Monge-Argiles JA; Monge-Garcia V; Gasparini-Berenguer R; Garcia-Perez C; Gabaldon-Torres L; Salas-Felipe J; Leiva-Santana C
    Rev Neurol; 2019 Aug; 69(3):89-93. PubMed ID: 31309997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.
    Grangeon L; Paquet C; Bombois S; Quillard-Muraine M; Martinaud O; Bourre B; Lefaucheur R; Nicolas G; Dumurgier J; Gerardin E; Jan M; Laplanche JL; Peoc'h K; Hugon J; Pasquier F; Maltête D; Hannequin D; Wallon D;
    J Alzheimers Dis; 2016; 51(3):905-13. PubMed ID: 26890785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.